Clinical symptoms in MOG-induced EAE mice significantly exacerbated following chondroitin sulfate A (CS-A) injection, whereas administration of a degraded product, CSPG-DS, caused dramatic inhibition of EAE development. Also, administration of CSPG-DS but not CS-A, after the onset of clinical symptoms of EAE, was able to suppress the disease. Further studies demonstrated that CS-A up-regulated STAT4 expression and thus, induced IFN-γ production and Th1 CD4 T cell differentiation. CS-A also up-regulated STAT3 and IL-23 expression and thus increased IL-17 producing T cells. CSPG-DS treatment both in vivo and in vitro decreased TNFα production from splenocytes. In vitro and in vivo studies indicated that CSPG-DS treatment in EAE mice significantly blocked migration of lymphocytes, whereas CS-A treatment increased lymphocyte infiltration in the brain.
Introduction
Multiple sclerosis (MS) is viewed as an autoimmune disease, however, neither the etiology nor the mechanism of disease is fully understood, and current treatments have only modest effect. The conceptual understanding of MS rests on the animal model of experimental autoimmune encephalomyelitis (EAE). It is widely believed that MS is an inflammatory attack on myelin and neurons orchestrated by myelin specific T cells (Holmoy, 2007) .
Chondroitin sulfate (CS) is a major component of the extracellular matrix of many connective tissues, including cartilage, bone, skin, ligaments and tendons. It is a sulfated glycosaminoglycan (GAG) composed of a long unbranched polysaccharide chain with a repeating disaccharide structure of N-acetylgalactosamine and glucuronic acid. CS is an ingredient found commonly in dietary supplements used as complementary and alternative medicine (CAM) to treat osteoarthritis (OA). Researchers conducted a 4-year study known as the Glucosamine/ chondroitin Arthritis Intervention Trial at 16 sites across the United States and found that the popular dietary supplement combination of glucosamine plus chondroitin sulfate did not provide significant relief from osteoarthritis pain among all participants. However, a smaller subgroup of study participants with moderate-to-severe pain showed significant relief with the combined supplements (Clegg et al., 2006) . A recent report also demonstrates that CS has a slight to moderate efficacy in the symptomatic treatment of OA, with an excellent safety profile (Monfort et al., 2008a) . The benefit of chondroitin sulfate in patients with OA is likely the result of a number of effects including its antiinflammatory activity (Monfort et al., 2008b) . Such findings suggest that CS may play an important role as a CAM that could potentially benefit patients suffering from other autoimmune diseases such as MS.
Chondroitin sulfate proteoglycan (CSPG), a matrix protein that occurs naturally in the CNS, is considered to be a major inhibitor of axonal regeneration and is known to participate in activation of the inflammatory response. The disaccharide degradation of CSPG by a specific enzyme, chondroitinase ABC, promotes repair (Rolls et al., 2004) . Thus it has been postulated that a disaccharidic degradation product of chondroitin sulfate proteoglycan (CSPG-DS), participates in the modulation of the inflammatory responses and can, therefore, promote recovery in immune-induced neuropathologies of the CNS, such as experimental autoimmune uveitis (EAU) and EAE (Rolls et al., 2006) . In these disease models, the dramatic increase in T cells infiltrating the CNS is far in excess of the numbers needed for regular maintenance. It has been reported that CSPG-DS markedly alleviated the clinical symptoms of EAE and protected against the neuronal loss in EAU (Rolls et al., 2006) .
Although the functions of chondroitin sulfate in OA have been extensively studies (Uebelhart, 2008; Uebelhart et al., 2006; Vangsness et al., 2009; Volpi, 2004) , the role of chondroitin sulfate in EAE is still unknown. Studies on the immune modulation by chondroitin sulfate and its degraded disaccharide in EAE will provide a novel effective therapeutic target for multiple sclerosis in the patients and have great implications in the elucidation of mechanisms underlying multiple sclerosis. In the current study, we provide evidence for the first time that CS-A, which is naturally present in the central nervous system, may play a role in enhancing the clinical symptoms of EAE, whereas its degraded product, CSPG-DS, inhibits EAE development. Thus, CSPG-DS may E-mail address: Mizti.Nagarkatti@uscmed.sc.edu (M. Nagarkatti).
